Table 1.
Studies, n (participants) |
Pooled | I2 (%) | ||
---|---|---|---|---|
effect sizes [95% CI] | Q-statistics | |||
Anxiety symptoms | ||||
Odds ratio | ||||
Overall studies | 6 (9579) | 1.55 [1.30–1.85] | 6.84 | 26.94 |
Quality assessment | ||||
High Quality | 4 (7599) | 1.45 [1.21–1.73] | 1.76 | 0.00 |
β c | 3 (2376) | 0.05 [−0.32–0.41] | 8.36 | 76.07 |
Pearson’s r d | 4 (2483) | 0.18 [0.10–0.27] | 11.13 | 73.04 |
Depressive symptoms | ||||
Odds ratio | ||||
Overall studies | 6 (13241) | 1.43 [1.14–1.80] | 15.22 | 67.16 |
Quality assessment | ||||
High Quality | 2 (4481) | 1.42 [0.69–2.90] | 0.33 | 0.00 |
β c | 3 (2574) | 0.08 [0.01–0.14] | 0.82 | 0.00 |
a Anxiety symptoms were ascertained using the GAD-7 (cut-off: 10), GHQ-28, GAD-2, PHQ-4, GAD-2, SAS, and DASS-21
b Depressive symptoms were ascertained by the DASS-21, WHO-5 (cut-off: 13), PHQ-9 (cut-off:10), GHQ-28, and PHQ-2
c Beta value calculated by linear regression analysis indicates the change in score over time in hours
d Correlation analysis
Β Beta value; CI Confidence Interval; DASS Subscale scores of Depression, Anxiety, and Stress Scale; GAD Generalized Anxiety Disorder; GHQ-28 General Health Questionnaire-28; PHQ Patient Health Questionnaire; SAS Self-Rating Anxiety Scale
* Significant results are in bold text